# Simplify 1 (NCT01969838)

> Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01969838
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Sierra Oncology LLC - a GSK company
- Conditions: Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis
- Interventions: Momelotinib; Ruxolitinib; Placebo to match momelotinib; Placebo to match ruxolitinib
- Enrollment: 432
- Primary outcome: Splenic Response Rate at Week 24

## Commentary we found

- YouTube: 48
- Podcasts: 27
- X threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=simplify-1-nct01969838

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01969838", "email": "<work email>"}; the inbox owner confirms by the emailed link.